LHC Group (LHCG) Stock Rating Reaffirmed by Jefferies Group

LHC Group (NASDAQ:LHCG)‘s stock had its “buy” rating reaffirmed by analysts at Jefferies Group in a report issued on Wednesday. They presently have a $84.00 target price on the health services provider’s stock. Jefferies Group’s price objective suggests a potential upside of 19.90% from the stock’s current price. Jefferies Group also issued estimates for LHC Group’s Q1 2018 earnings at $0.59 EPS, Q2 2018 earnings at $0.77 EPS, Q3 2018 earnings at $0.97 EPS, Q4 2018 earnings at $1.17 EPS, FY2018 earnings at $3.50 EPS and FY2019 earnings at $4.20 EPS.

LHCG has been the subject of several other reports. BidaskClub raised LHC Group from a “sell” rating to a “hold” rating in a report on Wednesday. Zacks Investment Research raised LHC Group from a “sell” rating to a “hold” rating in a report on Wednesday, January 31st. Oppenheimer reissued a “buy” rating and issued a $85.00 target price on shares of LHC Group in a report on Thursday, December 7th. Finally, Stephens set a $74.00 target price on LHC Group and gave the company a “buy” rating in a report on Friday, March 2nd. Three investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $76.80.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ LHCG traded down $0.60 during mid-day trading on Wednesday, hitting $70.06. 50,112 shares of the company were exchanged, compared to its average volume of 294,000. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.97 and a quick ratio of 1.97. LHC Group has a 1-year low of $51.38 and a 1-year high of $76.14. The company has a market cap of $1,271.00, a PE ratio of 29.20, a P/E/G ratio of 1.12 and a beta of 0.70.

LHC Group (NASDAQ:LHCG) last issued its quarterly earnings results on Wednesday, February 28th. The health services provider reported $0.62 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.62. LHC Group had a return on equity of 9.18% and a net margin of 4.67%. The firm had revenue of $292.40 million during the quarter, compared to the consensus estimate of $280.82 million. During the same period last year, the company earned $0.58 earnings per share. The company’s revenue for the quarter was up 24.2% on a year-over-year basis. analysts anticipate that LHC Group will post 3.5 earnings per share for the current fiscal year.

In other news, COO Donald Dwayne Stelly sold 14,216 shares of LHC Group stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $64.00, for a total transaction of $909,824.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 14.80% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Dalton Greiner Hartman Maher & Co. raised its stake in shares of LHC Group by 24.8% during the 4th quarter. Dalton Greiner Hartman Maher & Co. now owns 304,858 shares of the health services provider’s stock worth $18,673,000 after buying an additional 60,563 shares during the last quarter. Wasatch Advisors Inc. increased its position in LHC Group by 17.2% during the 4th quarter. Wasatch Advisors Inc. now owns 254,381 shares of the health services provider’s stock worth $15,581,000 after purchasing an additional 37,241 shares in the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its position in LHC Group by 558.3% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 200,000 shares of the health services provider’s stock worth $12,250,000 after purchasing an additional 169,620 shares in the last quarter. Renaissance Technologies LLC increased its position in LHC Group by 1,862.8% during the 4th quarter. Renaissance Technologies LLC now owns 184,500 shares of the health services provider’s stock worth $11,301,000 after purchasing an additional 175,100 shares in the last quarter. Finally, Deutsche Bank AG increased its position in LHC Group by 371.5% during the 4th quarter. Deutsche Bank AG now owns 148,880 shares of the health services provider’s stock worth $9,117,000 after purchasing an additional 117,301 shares in the last quarter. 89.87% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This news story was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3335459/lhc-group-lhcg-stock-rating-reaffirmed-by-jefferies-group.html.

About LHC Group

LHC Group, Inc is a holding company. The Company provides post-acute healthcare services to patients through its home nursing agencies, hospice agencies, community-based services agencies and long-term acute care hospitals (LTACHs). The Company operates through four segments: home health services, hospice services, community-based services and facility-based services.

Analyst Recommendations for LHC Group (NASDAQ:LHCG)

Receive News & Ratings for LHC Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LHC Group and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Quantstamp  Hits Market Cap of $102.59 Million
Quantstamp Hits Market Cap of $102.59 Million
Critical Contrast: Generac  and Franklin Electric
Critical Contrast: Generac and Franklin Electric
Head-To-Head Analysis: Avis Budget Group  and Ryder
Head-To-Head Analysis: Avis Budget Group and Ryder
Critical Comparison: GCP Applied Technologies  and Its Competitors
Critical Comparison: GCP Applied Technologies and Its Competitors
Zacks: Brokerages Anticipate Nightstar Therapeutics  to Announce -$0.39 Earnings Per Share
Zacks: Brokerages Anticipate Nightstar Therapeutics to Announce -$0.39 Earnings Per Share
Zacks: Analysts Expect NCR Co.  to Announce $0.44 EPS
Zacks: Analysts Expect NCR Co. to Announce $0.44 EPS


© 2006-2018 Ticker Report. Google+.